Beijing Medicass Biotechnologies, founded in the beginning of this new century, are focused primarily on 1) supply of APIs and advanced pharmaceutical intermediates which are manufactured in compliance with cGMP, 2) Contracted manufacture of cGMP APIs and advanced pharmaceutical intermediates and extracts, and 3) TCM-based new drug discovery and development.

Medicass Biotechnologies possesses a technical team that consists of a number of experts and researchers who have been educated and trained in US, Europe and China with years of experience in cGMP manufacturing of APIs and advanced pharmaceutical intermediates, particularly from Chinese medicinal plants. Our cGMP manufacturing and QC analytical facilities located in both Guilin and in Beijing have been audited by pharmaceutical companies from USA, Canada, Europe, Hong Kong, in addition to China SFDA. Our clients for contracted cGMP manufacture and supply of API and advanced pharmaceutical intermediates are from Europe, Canada, USA, Hong Kong, Korea and China.

Medicass, LED by a group of world-class researchers with both academic and industrial experience in pharmaceuticals, has a broad and innovative proprietary technology platform that enables us to discover and develop TCM-derived novel therapeutics, including both SCEs and large molecules. Our state of the art R & D and analytical facilities have been well established in Beijing and in Guilin, supporting and ensuring our R & D and manufacturing activities.